Galectin-3 as a Promising Prognostic Marker in Congenital Heart Disease

Marina Mauri^*
*Correspondence: Marina Mauri, Department of Genetics, University of Milan, 20122 Milan, Italy, Email:

Introduction

Congenital Heart Disease (CHD) is a complex condition characterized by structural abnormalities of the heart present at birth. It is a leading cause of infant mortality and poses significant challenges in predicting the long-term outcomes and prognosis for affected individuals. In recent years, researchers have turned their attention to galectin-3, a carbohydrate-binding protein with diverse functions, as a potential prognostic marker in CHD [1]. This comprehensive literature review aims to explore the role of galectin-3 in predicting outcomes in CHD and shed light on its potential as a promising prognostic indicator. Galectin-3 (Gal 3) is a clever supportive of fibrotic biomarker that can foresee both right and left heart brokenness brought about by different cardiovascular circumstances. Its demeanor is by all accounts dynamically changed with advancing cardiovascular redesigning processes, even before the beginning of cardiovascular breakdown. Subsequently, Gal 3 has been viewed as a singular indicator of intense and ongoing cardiovascular breakdown or to act as a feature of a coordinated biomarker board that can predict unfriendly heart results. In innate coronary illness, Gal 3 connects with cardiovascular mortality and entanglements in the two kids and grown-ups and is proposed as a remedial objective to switch the enactment of supportive of fibrosis pathways that lead to cardiovascular breakdown [2,3].

Description

Galectin-3 has emerged as an intriguing biomarker in various cardiovascular diseases due to its involvement in multiple cellular processes, including inflammation, fibrosis, and cardiac remodeling. Several studies have investigated the association between galectin-3 levels and clinical outcomes in CHD patients [4]. These studies have demonstrated that elevated galectin-3 levels are significantly correlated with adverse outcomes such as heart failure, arrhythmias, and overall mortality. Furthermore, galectin-3 has shown promise in predicting the progression and severity of specific CHD subtypes. For instance, in cases of pulmonary hypertension associated with CHD, elevated galectin-3 levels have been linked to the development of more severe pulmonary vascular disease and a poorer prognosis. Similarly, in individuals with tetralogy of Fallot, higher galectin-3 levels have been associated with increased right ventricular dysfunction and an elevated risk of adverse cardiac events [5]. The underlying mechanisms by which galectin-3 contributes to the pathophysiology of CHD are still being elucidated. It is believed that galectin-3 plays a role in the inflammatory response, fibrotic remodeling, and cardiac dysfunction observed in CHD patients. By influencing these processes, galectin-3 may serve as a valuable tool for risk stratification, disease monitoring, and potentially guiding therapeutic interventions in the future [6].

Conclusion

The available evidence strongly suggests that galectin-3 holds significant potential as a prognostic marker in congenital heart disease. Its association with adverse clinical outcomes, such as heart failure and mortality, as well as its ability to predict disease progression and severity in specific CHD subtypes, highlights its clinical relevance. However, further research is needed to establish standardized measurement methods, define optimal cut-off values, and assess its utility in larger and more diverse CHD populations. The integration of galectin-3 into clinical practice has the potential to enhance risk assessment, guide treatment decisions, and improve patient outcomes in the field of congenital heart disease. Continued investigation into the role of galectin-3 in CHD is warranted to fully understand its prognostic value and to explore its therapeutic potential.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Dagher, Sue F., John L. Wang and Ronald J. Patterson. "Identification of galectin-3 as a factor in pre-mRNA splicing." Proc Natl Acad Sci 92 (1995): 1213-1217.

Google Scholar, Crossref, Indexed at

2. Li, Liu-cheng, Jun Li and Jian Gao. "Functions of galectin-3 and its role in fibrotic diseases." J Pharmacol Exp Ther 351 (2014): 336-343.

Google Scholar, Crossref, Indexed at

3. Davidson, Peter J., Michael J. Davis, Ronald J. Patterson and Marie-Anne Ripoche et al. "Shuttling of galectin-3 between the nucleus and cytoplasm." Glycobiology 12 (2002): 329-337.

Google Scholar, Crossref, Indexed at

4. Clementy, Nicolas, Bruno Garcia, Clementine Andre and Arnaud Bisson, et al. "Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure." PLoS One 13 (2018): e0201517.

Google Scholar, Crossref, Indexed at

5. Cui, Yameng, Xin Qi, Anan Huang and Jiao Li, et al. "Differential and predictive value of galectin-3 and soluble suppression of tumorigenicity-2 (sST2) in heart failure with preserved ejection fraction." Med Sci Monit 24 (2018): 5139.

Google Scholar, Crossref, Indexed at

6. Chen, Szu-Chia, and Po-Lin Kuo. "The role of galectin-3 in the kidneys." Int J Mol Sci 17 (2016): 565.

Google Scholar, Crossref, Indexed at